Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Safety Study of USL261 in the Outpatient Treatment of Subjects With Seizure Clusters

Trial Profile

An Open-Label Safety Study of USL261 in the Outpatient Treatment of Subjects With Seizure Clusters

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Midazolam (Primary)
  • Indications Generalised epilepsy; Partial epilepsies; Seizures
  • Focus Adverse reactions
  • Acronyms ARTEMIS 2
  • Sponsors Proximagen; UCB; UCB Biopharma; Upsher-Smith
  • Most Recent Events

    • 31 Oct 2023 According to an UCB media release, a post hoc analysis from the Phase 3 open-label extension study of NAYZILAM published in Epilepsy & Behavior journal.
    • 31 Oct 2023 Results of a post hoc analysis from this study of NAYZILAM presented in an UCB media release.
    • 01 Jan 2023 Results assessing treatment satisfaction, level of anxiety, confidence about traveling with midazolam nasal spray (MDZ-NS), and health-related quality of life in patients with seizure clusters and their caregivers after repeated, intermittent use of MDZ-NS in the outpatient setting published in the Epilepsy and Behavior
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top